Global Parkinson Disease Drug Market Research Report, Competitive, Technology and Forecast Analysis 2025-2032
Description
Market Overview
According to DIResearch＇s in-depth investigation and research, the global Parkinson Disease Drug market size will reach 6,947.60 Million USD in 2025 and is projected to reach 10,655.35 Million USD by 2032, with a CAGR of 6.30% (2025-2032). Notably, the China Parkinson Disease Drug market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Parkinson＇s disease drugs are medications prescribed to individuals diagnosed with Parkinson＇s disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. These drugs are primarily aimed at alleviating the motor symptoms of the condition, which include tremors, muscle rigidity, and bradykinesia (slowness of movement). The most commonly prescribed class of drugs for Parkinson＇s disease are levodopa medications, which are converted to dopamine in the brain to help replenish the deficient neurotransmitter. Other drug classes, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, are also used to manage symptoms and extend the effectiveness of levodopa. While these drugs can provide significant relief from the motor symptoms, they do not cure Parkinson＇s disease, and their use may be tailored to each patient＇s specific needs and stage of the disease.
The major global suppliers of Parkinson Disease Drug include Merck, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, Roche, Bausch Health, H.Lundbeck, Supernus Pharmaceuticals, Orion, Stada Arzneimittel, Servier, Recordati, Changzhou Kangpu Pharmaceutical Co., Ltd, CSPC Pharmaceutical Group Limited, Zhejiang Jingxin Pharmaceutical Co., Ltd, Qilu Pharmaceutical, YiChang HEC ChangJiang Pharmaceutical Co., Ltd, ZEIN BIOTECHNOLOGY CO., LTD, Hunan Jiudian Pharmaceutical Co., Ltd, Luye Pharma, Shijiazhuang No.4 Pharmaceutical Co.,Ltd, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Parkinson Disease Drug. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Parkinson Disease Drug market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Parkinson Disease Drug market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Parkinson Disease Drug industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Parkinson Disease Drug Include:
Merck
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
Roche
Bausch Health
H.Lundbeck
Supernus Pharmaceuticals
Orion
Stada Arzneimittel
Servier
Recordati
Changzhou Kangpu Pharmaceutical Co., Ltd
CSPC Pharmaceutical Group Limited
Zhejiang Jingxin Pharmaceutical Co., Ltd
Qilu Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical Co., Ltd
ZEIN BIOTECHNOLOGY CO., LTD
Hunan Jiudian Pharmaceutical Co., Ltd
Luye Pharma
Shijiazhuang No.4 Pharmaceutical Co.,Ltd
Parkinson Disease Drug Product Segment Include:
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Others
Parkinson Disease Drug Product Application Include:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Parkinson Disease Drug Industry PESTEL Analysis
Chapter 3: Global Parkinson Disease Drug Industry Porter's Five Forces Analysis
Chapter 4: Global Parkinson Disease Drug Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Parkinson Disease Drug Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Parkinson Disease Drug Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Parkinson Disease Drug Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
According to DIResearch＇s in-depth investigation and research, the global Parkinson Disease Drug market size will reach 6,947.60 Million USD in 2025 and is projected to reach 10,655.35 Million USD by 2032, with a CAGR of 6.30% (2025-2032). Notably, the China Parkinson Disease Drug market has changed rapidly in the past few years. By 2025, China＇s market size is expected to be Million USD, representing approximately % of the global market share.
Research Summary
Parkinson＇s disease drugs are medications prescribed to individuals diagnosed with Parkinson＇s disease, a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. These drugs are primarily aimed at alleviating the motor symptoms of the condition, which include tremors, muscle rigidity, and bradykinesia (slowness of movement). The most commonly prescribed class of drugs for Parkinson＇s disease are levodopa medications, which are converted to dopamine in the brain to help replenish the deficient neurotransmitter. Other drug classes, such as dopamine agonists, MAO-B inhibitors, and COMT inhibitors, are also used to manage symptoms and extend the effectiveness of levodopa. While these drugs can provide significant relief from the motor symptoms, they do not cure Parkinson＇s disease, and their use may be tailored to each patient＇s specific needs and stage of the disease.
The major global suppliers of Parkinson Disease Drug include Merck, GSK, Novartis, Boehringer Ingelheim, Teva Pharmaceutical, Abbvie, Kyowa Hakko Kirin Pharma, Astellas Pharma, Desitin Arzneimittel, Endo Pharmaceuticals, Roche, Bausch Health, H.Lundbeck, Supernus Pharmaceuticals, Orion, Stada Arzneimittel, Servier, Recordati, Changzhou Kangpu Pharmaceutical Co., Ltd, CSPC Pharmaceutical Group Limited, Zhejiang Jingxin Pharmaceutical Co., Ltd, Qilu Pharmaceutical, YiChang HEC ChangJiang Pharmaceutical Co., Ltd, ZEIN BIOTECHNOLOGY CO., LTD, Hunan Jiudian Pharmaceutical Co., Ltd, Luye Pharma, Shijiazhuang No.4 Pharmaceutical Co.,Ltd, etc. The global players competition landscape in this report is divided into three tiers. The first tier comprises global leading enterprises that command a substantial market share, hold a dominant industry position, possess strong competitiveness and influence, and generate significant revenue. The second tier includes companies with a notable market presence and reputation; these firms actively follow industry leaders in product, service, or technological innovation and maintain a moderate revenue scale. The third tier consists of smaller companies with limited market share and lower brand recognition, primarily focused on local markets and generating comparatively lower revenue.
This report studies the market size, price trends and future development prospects of Parkinson Disease Drug. Focus on analysing the market share, product portfolio, prices, sales, revenue and gross profit margin of global major suppliers, as well as the market status and trends of different product types and applications in the global Parkinson Disease Drug market. The report data covers historical data from 2020 to 2024, based year in 2025 and forecast data from 2026 to 2032.
The regions and countries in the report include US, Germany, Japan, China, France, UK, South Korea, Canada, Italy, Russia, Mexico, Brazil, India, Vietnam, Thailand, South Africa and other regions, covering the Parkinson Disease Drug market conditions and future development trends of key regions and countries, combined with industry-related policies and the latest technological developments, analyze the development characteristics of Parkinson Disease Drug industries in various regions and countries, help companies understand the development characteristics of each region, help companies formulate business strategies, and achieve the ultimate goal of the company's global development strategy.
The data sources of this report mainly include the National Bureau of Statistics, customs databases, industry associations, corporate financial reports, third-party databases, etc. Among them, macroeconomic data mainly comes from the National Bureau of Statistics, International Economic Research Organization; industry statistical data mainly come from industry associations; company data mainly comes from interviews, public information collection, third-party reliable databases, and price data mainly comes from various markets monitoring database.
Global Key Suppliers of Parkinson Disease Drug Include:
Merck
GSK
Novartis
Boehringer Ingelheim
Teva Pharmaceutical
Abbvie
Kyowa Hakko Kirin Pharma
Astellas Pharma
Desitin Arzneimittel
Endo Pharmaceuticals
Roche
Bausch Health
H.Lundbeck
Supernus Pharmaceuticals
Orion
Stada Arzneimittel
Servier
Recordati
Changzhou Kangpu Pharmaceutical Co., Ltd
CSPC Pharmaceutical Group Limited
Zhejiang Jingxin Pharmaceutical Co., Ltd
Qilu Pharmaceutical
YiChang HEC ChangJiang Pharmaceutical Co., Ltd
ZEIN BIOTECHNOLOGY CO., LTD
Hunan Jiudian Pharmaceutical Co., Ltd
Luye Pharma
Shijiazhuang No.4 Pharmaceutical Co.,Ltd
Parkinson Disease Drug Product Segment Include:
Sinemet-CR
Trastal
Madopar
COMT Inhibitor
Others
Parkinson Disease Drug Product Application Include:
Under 40 Years Old
40-65 Years Old
Above 65 Years Old
Chapter Scope
Chapter 1: Product Research Range, Product Types and Applications, Market Overview, Market Situation and Trend
Chapter 2: Global Parkinson Disease Drug Industry PESTEL Analysis
Chapter 3: Global Parkinson Disease Drug Industry Porter's Five Forces Analysis
Chapter 4: Global Parkinson Disease Drug Major Regional Market Size (Revenue) and Forecast Analysis
Chapter 5: Global Parkinson Disease Drug Competitive Analysis of Key Suppliers (Revenue, Market Share, Regional Distribution and Industry Concentration)
Chapter 6: Global Parkinson Disease Drug Revenue and Forecast Analysis by Product Type
Chapter 7: Key Company Profiles (Product Portfolio, Revenue and Gross Margin)
Chapter 8: Industrial Chain Analysis, Parkinson Disease Drug Different Application Market Analysis (Revenue and Forecast) and Sales Channel Analysis
Chapter 9: Research Findings and Conclusion
Chapter 10: Methodology and Data Sources
Table of Contents
165 Pages
- 1 Parkinson Disease Drug Market Overview
- 1.1 Product Definition and Statistical Scope
- 1.2 Parkinson Disease Drug Product by Type
- 1.2.1 Sinemet-CR
- 1.2.2 Trastal
- 1.2.3 Madopar
- 1.2.4 COMT Inhibitor
- 1.2.5 Others
- 1.3 Parkinson Disease Drug Product by Application
- 1.3.1 Under 40 Years Old
- 1.3.2 40-65 Years Old
- 1.3.3 Above 65 Years Old
- 1.4 Global Parkinson Disease Drug Market Size Analysis (2020-2032)
- 1.5 Parkinson Disease Drug Market Development Status and Trends
- 1.5.1 Parkinson Disease Drug Industry Development Status Analysis
- 1.5.2 Parkinson Disease Drug Industry Development Trends Analysis
- 2 Parkinson Disease Drug Market PESTEL Analysis
- 2.1 Political Factors Analysis
- 2.2 Economic Factors Analysis
- 2.3 Social Factors Analysis
- 2.4 Technological Factors Analysis
- 2.5 Environmental Factors Analysis
- 2.6 Legal Factors Analysis
- 3 Parkinson Disease Drug Market Porter's Five Forces Analysis
- 3.1 Competitive Rivalry
- 3.2 Threat of New Entrants
- 3.3 Bargaining Power of Suppliers
- 3.4 Bargaining Power of Buyers
- 3.5 Threat of Substitutes
- 4 Global Parkinson Disease Drug Market Analysis by Country
- 4.1 Global Parkinson Disease Drug Market Size Analysis by Country: 2024 VS 2025 VS 2032
- 4.1.1 Global Parkinson Disease Drug Revenue Analysis by Country (2020-2025)
- 4.1.2 Global Parkinson Disease Drug Revenue Forecast Analysis by Country (2026-2032)
- 4.2 United States Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.3 Germany Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.4 Japan Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.5 China Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.6 France Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.7 U.K. Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.8 South Korea Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.9 Canada Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.10 Italy Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.11 Russia Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.12 Mexico Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.13 Brazil Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.14 India Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.15 Vietnam Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.16 Thailand Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 4.17 South Africa Parkinson Disease Drug Market Revenue and Growth Rate (2020-2032)
- 5 Competition by Suppliers
- 5.1 Global Parkinson Disease Drug Market Revenue by Key Suppliers (2021-2025)
- 5.2 Parkinson Disease Drug Competitive Landscape Analysis and Market Dynamic
- 5.2.1 Parkinson Disease Drug Competitive Landscape Analysis
- 5.2.2 Global Key Suppliers Headquarter and Key Area Sales
- 5.2.3 Market Dynamic
- 6 Parkinson Disease Drug Market Analysis by Type
- 6.1 Global Parkinson Disease Drug Market Size Analysis by Type: 2024 VS 2025 VS 2032
- 6.2 Global Parkinson Disease Drug Revenue and Forecast Analysis by Type (2020-2032)
- 7 Key Companies Analysis
- 7.1 Merck
- 7.1.1 Merck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.1.2 Merck Parkinson Disease Drug Product Portfolio
- 7.1.3 Merck Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.2 GSK
- 7.2.1 GSK Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.2.2 GSK Parkinson Disease Drug Product Portfolio
- 7.2.3 GSK Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.3 Novartis
- 7.3.1 Novartis Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.3.2 Novartis Parkinson Disease Drug Product Portfolio
- 7.3.3 Novartis Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.4 Boehringer Ingelheim
- 7.4.1 Boehringer Ingelheim Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.4.2 Boehringer Ingelheim Parkinson Disease Drug Product Portfolio
- 7.4.3 Boehringer Ingelheim Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.5 Teva Pharmaceutical
- 7.5.1 Teva Pharmaceutical Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.5.2 Teva Pharmaceutical Parkinson Disease Drug Product Portfolio
- 7.5.3 Teva Pharmaceutical Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.6 Abbvie
- 7.6.1 Abbvie Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.6.2 Abbvie Parkinson Disease Drug Product Portfolio
- 7.6.3 Abbvie Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.7 Kyowa Hakko Kirin Pharma
- 7.7.1 Kyowa Hakko Kirin Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.7.2 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Product Portfolio
- 7.7.3 Kyowa Hakko Kirin Pharma Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.8 Astellas Pharma
- 7.8.1 Astellas Pharma Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.8.2 Astellas Pharma Parkinson Disease Drug Product Portfolio
- 7.8.3 Astellas Pharma Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.9 Desitin Arzneimittel
- 7.9.1 Desitin Arzneimittel Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.9.2 Desitin Arzneimittel Parkinson Disease Drug Product Portfolio
- 7.9.3 Desitin Arzneimittel Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.10 Endo Pharmaceuticals
- 7.10.1 Endo Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.10.2 Endo Pharmaceuticals Parkinson Disease Drug Product Portfolio
- 7.10.3 Endo Pharmaceuticals Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.11 Roche
- 7.11.1 Roche Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.11.2 Roche Parkinson Disease Drug Product Portfolio
- 7.11.3 Roche Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.12 Bausch Health
- 7.12.1 Bausch Health Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.12.2 Bausch Health Parkinson Disease Drug Product Portfolio
- 7.12.3 Bausch Health Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.13 H.Lundbeck
- 7.13.1 H.Lundbeck Basic Company Profile (Employees, Areas Service, Competitors and Contact Information)
- 7.13.2 H.Lundbeck Parkinson Disease Drug Product Portfolio
- 7.13.3 H.Lundbeck Parkinson Disease Drug Market Data Analysis (Revenue, Gross Margin and Market Share) (2021-2025)
- 7.14 Supernus Pharmaceuticals
- 7.14.1 Supernus Pharmaceuticals Basic Company Profile (Employees, Areas Service, Competitors and Contact Informa
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
